Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
IRVINE, Calif., Sept. 25, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares from January 14, 2016 through July 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by September 29, 2017, the lead plaintiff motion deadline.
If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its New Drug Application (“NDA”) for Rexista; that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting enough data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
On July 24, 2017, scientists from the U.S. Food and Drug Administration (the “FDA”) expressed concerns that the Company failed to provide enough data about the abuse potential of Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s NDA for Rexista, citing insufficient data about the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, the Company’s share price lowered materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
